ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements
Shree Ganesh Bio-Tech (India) Limited has released its Annual Report for the financial year 2025-26. The 16th Annual General Meeting is scheduled for September 28, 2026.
Shree Ganesh Bio-Tech (India) Limited has issued a notice for its 16th Annual General Meeting. The meeting is scheduled for September 28, 2026, at the registered office.
Shree Ganesh Biotech (India) Limited has updated its official website address to www.shreeganeshbiotech.bar. Exchanges are requested to update their records accordingly.
Shree Ganesh Biotech (India) Limited has declared that it has no unutilised funds from any prior public issues, rights issues, or preferential placements as of June 2026.
Shree Ganesh Bio-Tech (India) Ltd reported revenue from operations of ₹1.4 Cr (+0.0% YoY) and a net loss of ₹0.6 Cr for Q1 FY27.
Shree Ganesh Bio-Tech has scheduled a board meeting for August 4, 2026, to consider and approve its un-audited financial results for the quarter ended June 30, 2026.
Shree Ganesh Biotech (India) Limited submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms adherence to SEBI regulations and listing requirements.
Shree Ganesh Bio-Tech (India) Ltd reported revenue from operations of ₹2.1 Cr (-30.0% YoY) and a net loss of ₹0.1 Cr for Q4 FY26.
Shree Ganesh Biotech (India) Ltd reported annual revenue of ₹4.97 Crore for FY2026. The board approved audited results with an unmodified audit opinion.
Shree Ganesh Biotech (India) Ltd has scheduled a Board of Directors meeting for May 14, 2026. The board will primarily consider and approve the audited standalone financial results for the quarter and year ended March 31, 2026.
Shree Ganesh Biotech (India) Ltd confirmed it does not meet the SEBI criteria for a 'Large Corporate' as of March 31, 2026. The company reported zero outstanding borrowings. Consequently, it is exempt from mandatory debt fundraising disclosures and compliance norms specified for Large Entities under SEBI circulars.
Shree Ganesh Bio-Tech (India) Ltd reported net profit of ₹0.3 Cr (-62.5% YoY) for Q3 FY26.